Inhibiting Soluble Epoxide Hydrolase Suppresses NF-κB p65 Signaling and Reduces CXCL10 Expression as a Potential Therapeutic Target in Hashimoto's Thyroiditis
The Journal of Clinical Endocrinology & Metabolism · 16.09.2024 · 109 (10) · 2579-2588
DOI: 10.1210/clinem/dgae163 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.03.2024. Verfasst von Jing Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730099, China. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Hashimoto Disease, Chemokine CXCL10, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Gansu Province, Science and Technology Innovation Platform Foundation of Gansu Provincial Hospital.
Abstract (Originalsprache)
Background
Although Hashimoto's thyroiditis (HT) is one of most common autoimmune thyroid diseases, its treatment remains focused on symptom relief. The soluble epoxide hydrolase (sEH) shows potential functions as a drug target in alleviating some autoimmune diseases; however, we seldom know its role in HT.
Methods
The protein expression of sEH and related downstream molecules were evaluated by immunohistochemistry, Western blotting, ELISA, or immunofluorescence staining. RNA sequencing of tissue samples was performed to analyze differential genes and dysregulated pathways in HT and controls. The thyroid follicular epithelial cells (TFECs) and rat HT model were used to verify the biological function of sEH and the inhibition role of adamantyl-ureido-dodecanoic acid (AUDA) in HT.
Results
The sEH was significantly upregulated in HT patients compared with healthy individuals. Transcriptome sequencing showed cytokine-related pathways and chemokine expression; especially chemokine CXCL10 and its receptor CXCR3 were aberrant in HT patients. In TFECs and a rat HT model, blocking sEH by AUDA inhibitor could effectively inhibit the autoantibody, proinflammatory nuclear kappa factor B (NF-κB) signaling, chemokine CXCL10/CXCR3 expression, and type-1 helper CD4+ T cells.
Conclusion
Our findings suggest that sEH/NF-κB p65/CXCL10-CXCR3 might be promising therapeutic targets for HT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730099, China.
- Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, Gansu 730099, China.
- Clinical Research Center for Metabolic Disease, Gansu Provincial Hospital, Lanzhou, Gansu 730099, China.
- Department of Biotherapy Center, Gansu Provincial Hospital, Lanzhou, Gansu 730099, China.
- Department of Pathology, Gansu Provincial Hospital, Lanzhou, Gansu 730099, China.
- Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, Gansu 730099, China.
ORCID-Profile: Limin Tian
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Gansu Province
- Science and Technology Innovation Platform Foundation of Gansu Provincial Hospital
- Lanzhou Science and Technology Plan
Zitieren
APA
Feng, J., Xu, X., Cai, W., Yang, X., Niu, R., Han, Z., & Tian, L. (2024). Inhibiting Soluble Epoxide Hydrolase Suppresses NF-κB p65 Signaling and Reduces CXCL10 Expression as a Potential Therapeutic Target in Hashimoto's Thyroiditis. The Journal of Clinical Endocrinology & Metabolism, 109(10), 2579-2588. https://doi.org/10.1210/clinem/dgae163
Vancouver
Feng J, Xu X, Cai W, Yang X, Niu R, Han Z, et al. Inhibiting Soluble Epoxide Hydrolase Suppresses NF-κB p65 Signaling and Reduces CXCL10 Expression as a Potential Therapeutic Target in Hashimoto's Thyroiditis. The Journal of Clinical Endocrinology & Metabolism. 2024;109(10):2579-2588. doi:10.1210/clinem/dgae163
BibTeX
@article{Feng2024,
author = {Feng, Jing and Xu, Xianghong and Cai, Wei and Yang, Xingwen and Niu, Ruilan and Han, Ziqi and Tian, Limin},
title = {Inhibiting Soluble Epoxide Hydrolase Suppresses NF-κB p65 Signaling and Reduces CXCL10 Expression as a Potential Therapeutic Target in Hashimoto's Thyroiditis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {10},
pages = {2579--2588},
doi = {10.1210/clinem/dgae163}
}
EUVIMED